-
Patrick S Tarpey,
F Lucy Raymond,
Lam S Nguyen,
Jayson Rodriguez,
Anna Hackett,
Lucianne Vandeleur,
Raffaella Smith,
Cheryl Shoubridge,
Sarah Edkins,
Claire Stevens, [......],
Duane Superneau,
Richard Wooster,
Martin Bobrow,
Gillian Turner,
Roger E Stevenson,
Charles E Schwartz,
P Andrew Futreal,
Anand K Srivastava,
Michael R Stratton,
Jozef Gécz
[show abstract]
[hide abstract]
ABSTRACT: Nonsense-mediated mRNA decay (NMD) is of universal biological significance. It has emerged as an important global RNA, DNA and translation regulatory pathway. By systematically sequencing 737 genes (annotated in the Vertebrate Genome Annotation database) on the human X chromosome in 250 families with X-linked mental retardation, we identified mutations in the UPF3 regulator of nonsense transcripts homolog B (yeast) (UPF3B) leading to protein truncations in three families: two with the Lujan-Fryns phenotype and one with the FG phenotype. We also identified a missense mutation in another family with nonsyndromic mental retardation. Three mutations lead to the introduction of a premature termination codon and subsequent NMD of mutant UPF3B mRNA. Protein blot analysis using lymphoblastoid cell lines from affected individuals showed an absence of the UPF3B protein in two families. The UPF3B protein is an important component of the NMD surveillance machinery. Our results directly implicate abnormalities of NMD in human disease and suggest at least partial redundancy of NMD pathways.
Nature Genetics 10/2007; 39(9):1127-33. · 35.53 Impact Factor
-
Patrick S Tarpey,
F Lucy Raymond,
Lam S Nguyen,
Jayson Rodriguez,
Anna Hackett,
Lucianne Vandeleur,
Raffaella Smith,
Cheryl Shoubridge,
Sarah Edkins,
Claire Stevens, [......],
Duane Superneau,
Richard Wooster,
Martin Bobrow,
Gillian Turner,
Roger E Stevenson,
Charles E Schwartz,
P Andrew Futreal,
Anand K Srivastava,
Michael R Stratton,
Jozef G|[eacute]|cz
Nature Genetics 08/2007; 39(9):1127-1133. · 35.53 Impact Factor
-
Lionel Willatt,
James Cox,
John Barber,
Elisabet Dachs Cabanas,
Amanda Collins,
Dian Donnai,
David R FitzPatrick,
Eddy Maher,
Howard Martin, Josep Parnau,
Lesley Pindar,
Jacqueline Ramsay,
Charles Shaw-Smith,
Erik A Sistermans,
Michael Tettenborn,
Dorothy Trump,
Bert B A de Vries,
Kate Walker,
F Lucy Raymond
[show abstract]
[hide abstract]
ABSTRACT: We report the identification of six patients with 3q29 microdeletion syndrome. The clinical phenotype is variable despite an almost identical deletion size. The phenotype includes mild-to-moderate mental retardation, with only slightly dysmorphic facial features that are similar in most patients: a long and narrow face, short philtrum, and high nasal bridge. Autism, gait ataxia, chest-wall deformity, and long and tapering fingers were noted in at least two of six patients. Additional features--including microcephaly, cleft lip and palate, horseshoe kidney and hypospadias, ligamentous laxity, recurrent middle ear infections, and abnormal pigmentation--were observed, but each feature was only found once, in a single patient. The microdeletion is approximately 1.5 Mb in length, with molecular boundaries mapping within the same or adjacent bacterial artificial chromosome (BAC) clones at either end of the deletion in all patients. The deletion encompasses 22 genes, including PAK2 and DLG1, which are autosomal homologues of two known X-linked mental retardation genes, PAK3 and DLG3. The presence of two nearly identical low-copy repeat sequences in BAC clones on each side of the deletion breakpoint suggests that nonallelic homologous recombination is the likely mechanism of disease causation in this syndrome.
The American Journal of Human Genetics 08/2005; 77(1):154-60. · 10.60 Impact Factor
-
Patrick Tarpey, Josep Parnau,
Matthew Blow,
Hayley Woffendin,
Graham Bignell,
Charles Cox,
James Cox,
Helen Davies,
Sarah Edkins,
Simon Holden, [......],
Roger Stevenson,
Charles Schwartz,
Ian Young,
Douglas Easton,
Martin Bobrow,
P Andrew Futreal,
Michael R Stratton,
Jozef Gecz,
Richard Wooster,
F Lucy Raymond
[show abstract]
[hide abstract]
ABSTRACT: We have identified truncating mutations in the human DLG3 (neuroendocrine dlg) gene in 4 of 329 families with moderate to severe X-linked mental retardation. DLG3 encodes synapse-associated protein 102 (SAP102), a member of the membrane-associated guanylate kinase protein family. Neuronal SAP102 is expressed during early brain development and is localized to the postsynaptic density of excitatory synapses. It is composed of three amino-terminal PDZ domains, an src homology domain, and a carboxyl-terminal guanylate kinase domain. The PDZ domains interact directly with the NR2 subunits of the NMDA glutamate receptor and with other proteins responsible for NMDA receptor localization, immobilization, and signaling. The mutations identified in this study all introduce premature stop codons within or before the third PDZ domain, and it is likely that this impairs the ability of SAP102 to interact with the NMDA receptor and/or other proteins involved in downstream NMDA receptor signaling pathways. NMDA receptors have been implicated in the induction of certain forms of synaptic plasticity, such as long-term potentiation and long-term depression, and these changes in synaptic efficacy have been proposed as neural mechanisms underlying memory and learning. The disruption of NMDA receptor targeting or signaling, as a result of the loss of SAP102, may lead to altered synaptic plasticity and may explain the intellectual impairment observed in individuals with DLG3 mutations.
The American Journal of Human Genetics 09/2004; 75(2):318-24. · 10.60 Impact Factor
